| Name | Indomethacin |
| Description | Indomethacin is an orally active nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase enzymes COX-1 and COX-2, with IC₅₀ values of 18 nM and 26 nM, respectively. It exhibits good blood-brain barrier permeability and shows significant anti-inflammatory, anti-tumor, and anti-infective activities. Indomethacin is widely used in research related to cancer, inflammation, and viral infections, and is also commonly used to induce gastric ulcer models in animals. |
| In vitro | METHODS: Human gastric cancer cells AGS were treated with Indomethacin (100-500 µM) for 24 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: Indomethacin increased LC3-II protein levels in AGS cells, which may be a result of induction of autophagy or inhibition of lysosome-dependent autophagic degradation. [1]
METHODS: Human tumor cells HT29 and A431 were treated with Indomethacin (1-10 µM) and EGF (25 ng/mL) for 24-48 h. Cell migration was detected by wound-healing assay.
RESULTS: Indomethacin inhibited HT29 cell migration. After treating A431 cells with EGF only, the wound closed within 24 h, but the wound remained open after 24 h of treatment with Indomethacin. [2] |
| In vivo | METHODS: To test the antitumor activity in vivo, Indomethacin (1 mg/kg) was administered by gavage to CDF1 mice bearing Colon 26 xenografts twice daily for 7-21 days.
RESULTS: Mean tumor weight was significantly lower in both the long-term and short-term Indomethacin administration groups, serum immunosuppressive acidic protein levels were significantly lower, serum IL-6 levels were also significantly lower, and prostaglandin E2 levels in tumor tissues were significantly lower than those in the control group. [3] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 104 mg/mL (290.67 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.58 mg/mL (10.01 mM), Solution.
Ethanol : 17.9 mg/mL (50.03 mM), Heating is recommended.
|
| Keywords | PLA2 | PDE2 | Inhibitor | inhibit | inflammation | Indomethacin | Cyclooxygenase | COX-2 | COX-1 | COX | Autophagy | anti-infective | anticancer |
| Inhibitors Related | Neomycin sulfate | Stavudine | Aceglutamide | Hemin | Tamoxifen | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Hydroxychloroquine | Paeonol | Naringin | Trometamol | Alginic acid |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Inflammatory Traditional Chinese Medicine Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
United States
